We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company


  Silver Develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry, as... read more Featured Products: More products

Download Mobile App

Medix Biochemica Celebrates Launch of New Molecular Diagnostic Reagents Division at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
Print article
Image: Medix Biochemica at MEDICA 2021 (Photo courtesy of Medix Biochemica)
Image: Medix Biochemica at MEDICA 2021 (Photo courtesy of Medix Biochemica)

Medix Biochemica (Espoo, Finland) celebrated the launch of its new molecular diagnostic reagents division, MedixMDx at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 15-18 November in Düsseldorf, Germany.

Medix, including Lee Biosolutions, EastCoast Bio and Diaclone, is a leading global supplier of critical raw materials used for in vitro diagnostics (IVD). Medix recently acquired Diaclone, a prominent provider of monoclonal antibodies in the areas of inflammation, oncology, and immunology. At MEDICA 2021, Medix showcased its wide portfolio of monoclonal antibodies, antigens for immunoassay materials, molecular diagnostics reagents, enzymes for clinical chemistry controls, and biochemicals and biological.

Medix highlighted its range of quality reagents offered through MedixMDx in combination with a host of custom services to provide IVD kit manufacturers, labs and research institutions with the tailored support they need from proof-of-concept right through to release for sale. In addition to highlighting its wide range of high-quality reagents and master mixes designed to shorten development timelines and work with various assay technologies, Medix also threw light on its technical support provided to clients as they develop their assays as well as contract manufacturing services.

Medix highlighted its broad range of platform-agnostic reagents, including enzymes, nucleic acid extraction products, buffers and as well as consumables. The company showcased its range of enzymes, ready mixes, controls, clinical specimens and general reagents in the areas of PCR/qPCR, isothermal nucleic acid amplification technologies (iNAAT), Next generation Sequencing (NGS).

Related Links:
Medix Biochemica 

Gold Supplier
Quality Control Material
Multichem U
Platinum Supplier
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Automated Nucleic Acid Extraction System
SARS-CoV-2 IgG Antibodies Anti-S1 Assay
iRapid SARS-CoV-2 Quant "Neutralizing" Ab

Print article



view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.